TheMinistry of Healthsigned a 17.1 million euro contract with the companyInter Pharmafor the acquisition of the famous batch of failed tests to detect the coronavirus, manufactured by the Chinese companyBioeasy Biotechnology. EL MUNDO has had exclusive access to official documentation, which finally reveals the cost of the almost 700,000 useless tests to quickly detect the coronavirus. This documentation reflects the demand for a refund from the Executive of 6,988,035 euros that he had already paid.
The contract contemplates the specific acquisition of 659,000 diagnostic test units for the Covid-19 for a partial amount of 6 million plus VAT, corresponding to 35% of the total amount committed. The agreement was initialed between thegovernmentfrom Pedro Snchez and Inter Pharma on March 18 and this is the amount that has just been demanded to be reimbursed.
The Government has disbursed 350,293,032.08 euros in medical supplies and has carried out the acquisition of rapid detection systems for Covd-19 through the aforementioned contract, which, according to the file in the possession of this newspaper, has “been annulled by showing that the sensitivity of the products was lower than desired. ” Not surprisingly, the same, which was offered by the Chinese company Bioeasy Biotechnology with a percentage higher than 90%, only reached difficulties with 25/30% in the large Spanish hospitals. A figure that all specialists consider completely insufficient and that forced the Executive to proceed with the return of the consignment of material.
The contracting file also contains a letter sent by the Ministry of Health to the Inter Pharma intermediary in which it communicates that “the antigen detection technique” of the coronavirus “must have more than 80% sensitivity and 99% of specificity. ” Well, it adds that “on March 21 and 25, 2020, the first two deliveries of the four planned for the aforementioned supply took place, having included in the second of them different rapid antigen detection kits from the company Bioeasy before the sensitivity problems noted in the tests included in the first game. “
“TheCarlos III Health InstituteAfter carrying out the corresponding reliability studies on the tests provided, “Sanidad reprimands in its letter,” he concluded in his report of March 24, 2020 that ‘the sensitivity of the rapid test is much lower in our environment than indicated the clinical validation by which the CE marking was obtained (24.3% in our environment vs. 83% of the CE marking) and in their report of March 30, 2020 that ‘the sensitivity of the rapid test’ of the new model with fluorescence “It is lower in our environment than indicated by the clinical validation for which the CE marking was obtained (57.8% in our environment vs. 92% of the clinical validation presented by the manufacturer).”
“Consequently”, Healthcare abounded, the goods supplied not being fit for the intended purpose, as a consequence of the vices or defects observed in them and attributable to Inter Pharma and the presumption that the replacement or repair of said goods would not be sufficient To achieve that end, “Health” completely “rejects the delivered material. Then, it was left” on Inter Pharma’s account, this contracting body being exempt from the obligations of receipt and payment for the rest of the supply. ” required Inter Pharma “for the recovery of the satisfied price, which amounts to 6,998,035 euros (VAT included), corresponding to invoices number 120/2117, 120/2191 and 120/2215”.
After advancing this newspaper exclusively the contract, Inter Pharma issued a press release stating that its “sole objective has been to offer an alternative that could be useful in the early detection of Covid-19, conditioning the supply of test them for validation by the Spanish health authorities. ” This company underlines that “the company through which these tests were acquired,Shenzhen Biotechnology, had at the time of the license agreement to export their products and the tests have the CE marking and the TV certificate that allow their marketing and sale in theEuropean UnionLikewise, it adds that “the manufacturer provided the required documentation on the certifications, clinical studies and protocols for use, which was forwarded to the Spanish authorities, which analyzed and validated it.”
According to the criteria of